Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL397466 | 0.87 | ALDH1A1 (0.59) | ALDH1A1L3MBTL1KDM4EKMT2ATSHR | |
| Hydrochloric Acid SCHEMBL28115566 | 0.85 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1KDM4EKMT2ATSHR | |
| Acetic Acid SCHEMBL27614844 | 0.80 | CYP2A6 (0.54) | KMT2ATSHRLMNAMEN1SCN9A | |
| Acetic Acid SCHEMBL7836902 | 0.79 | TSHR (0.68) | ALDH1A1KDM4EKMT2ATSHRLMNA | |
| Acetic Acid SCHEMBL28224071 | 0.79 | CYP2A6 (0.52) | KMT2ATSHRLMNAMEN1SCN9A | |
| Acetic Acid SCHEMBL27746609 | 0.79 | CYP2A6 (0.52) | KMT2ATSHRLMNAMEN1SCN9A | |
| Acetic Acid SCHEMBL28219393 | 0.79 | CYP2A6 (0.52) | KMT2ATSHRLMNAMEN1SCN9A | |
| Acetic Acid SCHEMBL27431020 | 0.79 | CYP2A6 (0.52) | KMT2ATSHRLMNAMEN1SCN9A | |
| Acetic Acid SCHEMBL27630446 | 0.79 | CYP2A6 (0.52) | KMT2ATSHRLMNAMEN1SCN9A | |
| Acetic Acid SCHEMBL27942328 | 0.79 | DHODH (0.55) | KMT2ATSHRLMNAMEN1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946170-B8 | DICLOFENAC FOR THE TREATMENT OF VASCULOPATHIES | GLYCADIA INC (US) | 2005-12-07 | — | — | EP | claimed |
| JP-2002515031-A | — | — | 2002-05-21 | — | — | JP | claimed |
| EP-0946170-A4 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL INC (US) | 2002-03-20 | — | — | EP | claimed |
| EP-0946170-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1997029746-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1997-08-21 | — | — | WO | claimed |
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-25 | — | — | US | disclosed |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | TECHFIELDS PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-9872846-B2 | High penetration compositions and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2018-01-23 | — | — | US | disclosed |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO LTD (CN) | 2017-07-27 | — | — | US | disclosed |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-07-27 | — | — | US | disclosed |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | PREMIER RESEARCH INTERNATIONAL, LLC | 2015-03-12 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| EP-0946170-B8 | DICLOFENAC FOR THE TREATMENT OF VASCULOPATHIES | GLYCADIA INC (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-0946170-A4 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL INC (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-0946170-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1997029746-A1 | INHIBITION OF PROTEIN GLYCATION AND PREVENTION OF VASCULOPATHY | EXOCELL, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226084-A9 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN5A 1669/4885ALDH1A1 1724/4885L3MBTL1 4827/4885 |
| US-20240115562-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN5A 1669/4885ALDH1A1 1724/4885L3MBTL1 4827/4885 |
| US-20150072961-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN5A 1669/4885ALDH1A1 1724/4885L3MBTL1 4827/4885 |
| US-20240131017-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | HRH4, HCAR2, PAH | SCN5A 1669/4885ALDH1A1 1724/4885L3MBTL1 4827/4885 |
| US-20170209404-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SCN5A 1293/4885ALDH1A1 1790/4885L3MBTL1 4866/4885 |
| US-20170209585-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SCN5A 1293/4885ALDH1A1 1790/4885L3MBTL1 4866/4885 |
| US-11857545-B2 | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | HRH4, HCAR2, PAH | SCN5A 1669/4885ALDH1A1 1724/4885L3MBTL1 4827/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SCN5A 1293/4885ALDH1A1 1790/4885L3MBTL1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.